(^∀^) try 1ClickGram.com download instagram videos and photos

Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer

Say and pronounce Dr. Plimack On on SuperTTS.com Make Your Own Text-To-Speech Words Instantly

  Info

Description

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.

Tags

cancer oncology
  Email Video to Friends   Receive Emails for Similar Videos

Email:

  Repeat and Loop Video   Link to Video   Create Short URL  Publish Text About This Video   Share on Facebook, Twitter, and more
  See Recommended Videos For You
Old Cartoons on DVD. Visit and Bookmark: Cool90s.com!

Related

  The Future of Bladder Cancer Research   Dr. Garcia on Sequencing Immunotherapies in Bladder Cancer   Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer   Prognostic Subgroups in Advanced Bladder Cancer   PD-L1 Expression in Bladder Cancer   Dr. Sklar on Challenges With Clinical Trials in Bladder Cancer   Combination Trials in Advanced Bladder Cancer   FDA Approval of Atezolizumab for Advanced Bladder Cancer   Bladder Cancer: Real-World Experience With Immunotherapy   Immunotherapy Toxicity Management in Bladder Cancer   Dr. Andrea Apolo on Treatment Challenges in Metastatic Bladder Cancer   Activity of Immunotherapy in the Frontline Setting   Update on Durvalumab for Metastatic Bladder Cancer   Chemotherapy Following Immunotherapy in Bladder Cancer   BCG-Refractory Superficial Bladder Cancer   Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma   Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer   Dr. Konety on Guidelines for the Management of Bladder Cancer   Bladder Cancer: Monoclonal Antibodies Under Investigation   Erik P. Castle, M.D.: Urologist - Mayo Clinic   Bladder Cancer Recurrence Discovered Through New Urine Test   Bradley C. Leibovich, M.D.: Urologist - Mayo Clinic   Dr. Black on Combinations with Durvalumab in Bladder Cancer   Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer   Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma   Dr. Garon on Incorporating Immunotherapies into Lung Cancer Treatment   Dr. David Nanus on Atezolizumab for Urothelial Bladder Cancer   Dr. Daneshmand on Blue Light Cystoscopy for Bladder Cancer   Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer   Scancell "very optimistic" about US study after "compelling" melanoma trial results   Bladder cancer survivor talks about fight   Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines   Dr. Rosenburg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines   Dr. Gary Steinberg on New AUA Guidelines for Bladder Cancer   Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer   Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and Breakthrough Designation in NSCLC   R. Jeffrey Karnes, M.D.: Urologist - Mayo Clinic   Managing Renal Pelvis Transitional Cell Carcinoma   PD-L1 Immunotherapy in Bladder Cancer   Bladder Cancer: Immunotherapy in the Perioperative Setting   Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma   FDA Approvals in HCC and Gastric Cancer, ODAC Panel Splits on Adjuvant RCC Treatment, and More   Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, and More   Dr. Gomella Discusses Immunotherapy in Bladder Cancer   FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC   Dr. Garcia on Selecting Second-line Immunotherapy in Bladder Cancer   Dr. Petrylak Discusses Progress With Bladder Cancer Agents   Unmet Needs: Sequencing After Immunotherapy in NSCLC   Dr. De Santis on the Future Treatment Landscape for Bladder Cancer   Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer   Dr. Plimack on KEYNOTE-045 Trial for Pembrolizumab in Urothelial Carcinoma   Dr. Andrea Apolo on Avelumab in Metastatic Bladder Cancer   FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year   Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer   Dr. Levine on Challenges in Ovarian Cancer   Dr. Chase on Challenges Facing Gynecologic Cancer   Dr. Black on Sequencing of Immunotherapy in Bladder Cancer   Dr. Rosenberg on Frontline Immunotherapy Potential in Bladder Cancer   Bladder Cancer: Paradigm Changing Advances in Treatment   Dr. Marshall on Challenges With Cancer Moonshot Initiative   Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer   Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer   Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer   Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer   Dr. Black on Selecting Immunotherapy Agents in Bladder Cancer   Dr. Nanus on Clinical Trials Exploring Immunotherapy in Bladder Cancer   Dr. Petrylak on Novel Immunotherapy Research in Bladder Cancer   FDA Approval of Durvalumab for Bladder Cancer   Historic Perspective on Bladder Cancer Treatment   Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer   FDA Approval in Carcinoid Syndrome Diarrhea, Priority Reviews in Bladder Cancer and NSCLC, and More   Vincent DeVita "The Death of Cancer"   Dr. Moul on Challenges in Sequencing Therapies for Prostate Cancer   Dr. Inman Discusses the Biology of Bladder Cancer

Popular Today